Design considerations for nanotherapeutics in oncology
| Autor: | Stylianopoulos, T., Jain, R. K. |
|---|---|
| Přispěvatelé: | Stylianopoulos, T. [0000-0002-3093-1696] |
| Rok vydání: | 2015 |
| Předmět: |
Medical nanotechnology
Oncology cancer patient Cancer therapy Pharmaceutical Science Medicine (miscellaneous) Diseases Review Drug Delivery Systems phase 3 clinical trial (topic) Neoplasms binding affinity drug delivery system Nanoparticle formulation Nanotechnology animal General Materials Science antineoplastic agent nanotechnology nanoparticle Enhanced Permeability and Retention effect particle size EPR effect unclassified drug phase 4 clinical trial (topic) Nanomedicine Tumor microenvironment Drug delivery Molecular Medicine intracellular transport medicine.medical_specialty Design overall survival phase 1 clinical trial (topic) Biomedical Engineering Antineoplastic Agents Bioengineering Enhanced permeability and retention effect chemistry Article Nanoparticle targeting Internal medicine medicine Animals Humans human procedures delayed release formulation Chemotherapeutic agents Adverse effect Tumors Controlled drug release business.industry Cancer medicine.disease drug efficacy drug formulation quality of life Targeted drug delivery Delayed-Action Preparations phase 2 clinical trial (topic) Quality of Life Nanoparticles solid tumor Nanocarriers business metabolism |
| Zdroj: | Nanomedicine: Nanotechnology, Biology, and Medicine |
| ISSN: | 1549-9634 |
| DOI: | 10.1016/j.nano.2015.07.015 |
| Popis: | Nanotherapeutics have improved the quality of life of cancer patients, primarily by reducing the adverse effects of chemotherapeutic agents, but improvements in overall survival are modest. This is in large part due to the fact that the enhanced permeability and retention effect, which is the basis for the use of nanoparticles in cancer, can be also a barrier to the delivery of nanomedicines. A careful design of nanoparticle formulations can overcome barriers posed by the tumor microenvironment and result in better treatments. In this review, we first discuss strengths and limitations of clinically-approved nanoparticles. Then, we evaluate design parameters that can be modulated to optimize delivery. The benefits of active tumor targeting and drug release rate on intratumoral delivery and treatment efficacy are also discussed. Finally, we suggest specific design strategies that should optimize delivery to most solid tumors and discuss under what conditions active targeting would be beneficial. From the Clinical Editor: Advances in nanotechnology have seen the introduction of new treatment modalities for cancer. The principle of action using nanocarriers for drug delivery is based mostly on the Enhanced Permeability and Retention effect. This phenomenon however, can also be a hindrance. In this article, the authors performed an in-depth review on various nanoparticle platforms in cancer therapeutics. They also suggested options to improve drug delivery, in terms of carrier design. © 2015 Elsevier Inc. 11 1893 1907 1893-1907 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect